Aditxt Inc (ADTX)

$0.59 -0.02 (-3.49%)
Market Cap 444,000.00
Revenue (ttm) 130,000.00
Net Income (ttm) -34.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26,500.00%
Debt to Equity Ratio 0.00
Volume 133,900
Avg Vol 2,744,900
Day's Range N/A - N/A
Shares Out 731,000.00
Stochastic %K 3%
Beta 1.49
Analysts Strong Buy
Price Target $61.00

Company Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 870 1200
Address:
2569 Wyandotte Street, Suite 101, Mountain View, United States
ChuckNazty
ChuckNazty Feb. 19 at 11:38 AM
$ADTX Ok that’s some math…. WHATS THE PRODUCT? WHATS THE PLAN??? WHERE IS THE MONEY??? ANSWER: -The product is the stock -The plan is to dilute and RS shareholders over and over -The money is being stolen by $ADTX management The only LMFAO is amro on his way to the bank with investors money
0 · Reply
alfredchchspain
alfredchchspain Feb. 19 at 11:15 AM
$ADTX ¡¡¡¡¡ SCAM !!!!!
0 · Reply
F74
F74 Feb. 19 at 10:01 AM
$ADTX dilution rs dilution rs ! scam ! sec !!!
0 · Reply
exile0002
exile0002 Feb. 19 at 9:16 AM
$ADTX hope this fraud will end sooner than later and they bring Amro and his gang into prison !!!👎👎👎
1 · Reply
ChuckNazty
ChuckNazty Feb. 19 at 6:09 AM
$ADTX The only reason I keep ADTX on my watchlist is so I can check every day for bankruptcy/delist news… I lost 90% of my investment last year after reverse splits and it was a very valuable lesson I needed to learn about due diligence. I can’t believe there is going to be another reverse split For context: say that you bought 5000 ADTX shares in January 2025… after the upcoming reverse split you will have 1 share left Does ADTX even have a product? Does amro even have a plan? Where’s all the money?
0 · Reply
Champing
Champing Feb. 18 at 5:43 PM
$CETX :: $ADTX I Recommend that all Shareholders of $CETX & $ADTX Respectively, MUST join me on this protest: 1. SACK @GOVIL SAAGAR OF $CETX. HE IS A CRIMINAL AND STINGY MAN AND LACKS CREDIBILITY AND ACCOUNTABILITY AND DOESN'T HAVE THE INTEREST OF INVESTORS @HEART! 2. SACK @amro .A. ALBANNA IS A CRIMINAL AND STINGY MAN AND LACKS CREDIBILITY AND ACCOUNTABILITY AND DOESN'T HAVE THE INTEREST OF INVESTORS @HEART! These 2 company's are cunningly weaponizing R/S to fraud investors money and DESTROY THEIR shareholding capacity. Very wicked leaderships who does not give nor showcase: credibility and transparency and accountability and integrity in their leadership positions. @SEC Sack them All!
1 · Reply
Champing
Champing Feb. 18 at 5:27 PM
$CETX $ADTX I Recommend that all Shareholders of $CETX join me on this protest: 1. SACK @GOVIL SAAGAR HE IS A CRIMINAL AND STINGY MAN 2. SACK @AMRO .A. ALBANNA IS A CRIMINAL AND STINGY MAN These 2 company's are cunningly weaponizing R/S to fraud investors money and shares holding capacity. Very wicked leaderships who does not give nor showcase: credibility and transparency and accountability and integrity in their leadership positions. @Sec Sack them All! They These
0 · Reply
DailySqueezer
DailySqueezer Feb. 18 at 12:40 PM
$ADTX $ABP $NCEL $NVA 2
0 · Reply
alfredchchspain
alfredchchspain Feb. 18 at 9:02 AM
$ADTX NASDAQ CORRUPTO,SCAM.-99.98%
0 · Reply
MrAlientrader
MrAlientrader Feb. 17 at 9:17 PM
$ADTX be realistic guys, you will never get you money back at this stock, this isnshorts wonderland
0 · Reply
Latest News on ADTX
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Nov 18, 2025, 8:00 AM EST - 3 months ago

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Oct 29, 2025, 4:30 PM EDT - 4 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 27, 2025, 8:30 AM EDT - 4 months ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Evofem Announces Voting Results from Special Meeting of Stockholders

Oct 20, 2025, 4:19 PM EDT - 4 months ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 11, 2025, 9:18 AM EDT - 5 months ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Sep 9, 2025, 9:28 AM EDT - 5 months ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 25, 2025, 9:15 AM EDT - 6 months ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 21, 2025, 8:56 AM EDT - 6 months ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 19, 2025, 9:39 AM EDT - 6 months ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 14, 2025, 8:46 AM EDT - 6 months ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 11, 2025, 8:30 AM EDT - 6 months ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aug 5, 2025, 8:46 AM EDT - 7 months ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 29, 2025, 9:00 AM EDT - 7 months ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 24, 2025, 8:15 AM EDT - 7 months ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 22, 2025, 8:15 AM EDT - 7 months ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 15, 2025, 9:12 AM EDT - 7 months ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jul 7, 2025, 8:15 AM EDT - 8 months ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 26, 2025, 8:15 AM EDT - 8 months ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 11, 2025, 8:14 AM EDT - 9 months ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 9, 2025, 8:15 AM EDT - 9 months ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Jun 5, 2025, 8:15 AM EDT - 9 months ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 9 months ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

May 2, 2025, 9:00 AM EDT - 10 months ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 17, 2025, 8:15 AM EDT - 11 months ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 16, 2025, 8:15 AM EDT - 11 months ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 14, 2025, 8:15 AM EDT - 11 months ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 11, 2025, 8:15 AM EDT - 11 months ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 11 months ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Apr 2, 2025, 8:15 AM EDT - 11 months ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 28, 2025, 8:15 AM EDT - 11 months ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 11 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 24, 2025, 8:15 AM EDT - 11 months ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 17, 2025, 8:15 AM EDT - 1 year ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Mar 6, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 21, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Feb 13, 2025, 8:15 AM EST - 1 year ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 1 year ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:30 AM EST - 1 year ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Nov 6, 2024, 8:00 AM EST - 1 year ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 30, 2024, 5:00 PM EDT - 1 year ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 29, 2024, 8:15 AM EDT - 1 year ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 28, 2024, 8:15 AM EDT - 1 year ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 21, 2024, 8:15 AM EDT - 1 year ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Oct 10, 2024, 8:15 AM EDT - 1 year ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

ChuckNazty
ChuckNazty Feb. 19 at 11:38 AM
$ADTX Ok that’s some math…. WHATS THE PRODUCT? WHATS THE PLAN??? WHERE IS THE MONEY??? ANSWER: -The product is the stock -The plan is to dilute and RS shareholders over and over -The money is being stolen by $ADTX management The only LMFAO is amro on his way to the bank with investors money
0 · Reply
alfredchchspain
alfredchchspain Feb. 19 at 11:15 AM
$ADTX ¡¡¡¡¡ SCAM !!!!!
0 · Reply
F74
F74 Feb. 19 at 10:01 AM
$ADTX dilution rs dilution rs ! scam ! sec !!!
0 · Reply
exile0002
exile0002 Feb. 19 at 9:16 AM
$ADTX hope this fraud will end sooner than later and they bring Amro and his gang into prison !!!👎👎👎
1 · Reply
ChuckNazty
ChuckNazty Feb. 19 at 6:09 AM
$ADTX The only reason I keep ADTX on my watchlist is so I can check every day for bankruptcy/delist news… I lost 90% of my investment last year after reverse splits and it was a very valuable lesson I needed to learn about due diligence. I can’t believe there is going to be another reverse split For context: say that you bought 5000 ADTX shares in January 2025… after the upcoming reverse split you will have 1 share left Does ADTX even have a product? Does amro even have a plan? Where’s all the money?
0 · Reply
Champing
Champing Feb. 18 at 5:43 PM
$CETX :: $ADTX I Recommend that all Shareholders of $CETX & $ADTX Respectively, MUST join me on this protest: 1. SACK @GOVIL SAAGAR OF $CETX. HE IS A CRIMINAL AND STINGY MAN AND LACKS CREDIBILITY AND ACCOUNTABILITY AND DOESN'T HAVE THE INTEREST OF INVESTORS @HEART! 2. SACK @amro .A. ALBANNA IS A CRIMINAL AND STINGY MAN AND LACKS CREDIBILITY AND ACCOUNTABILITY AND DOESN'T HAVE THE INTEREST OF INVESTORS @HEART! These 2 company's are cunningly weaponizing R/S to fraud investors money and DESTROY THEIR shareholding capacity. Very wicked leaderships who does not give nor showcase: credibility and transparency and accountability and integrity in their leadership positions. @SEC Sack them All!
1 · Reply
Champing
Champing Feb. 18 at 5:27 PM
$CETX $ADTX I Recommend that all Shareholders of $CETX join me on this protest: 1. SACK @GOVIL SAAGAR HE IS A CRIMINAL AND STINGY MAN 2. SACK @AMRO .A. ALBANNA IS A CRIMINAL AND STINGY MAN These 2 company's are cunningly weaponizing R/S to fraud investors money and shares holding capacity. Very wicked leaderships who does not give nor showcase: credibility and transparency and accountability and integrity in their leadership positions. @Sec Sack them All! They These
0 · Reply
DailySqueezer
DailySqueezer Feb. 18 at 12:40 PM
$ADTX $ABP $NCEL $NVA 2
0 · Reply
alfredchchspain
alfredchchspain Feb. 18 at 9:02 AM
$ADTX NASDAQ CORRUPTO,SCAM.-99.98%
0 · Reply
MrAlientrader
MrAlientrader Feb. 17 at 9:17 PM
$ADTX be realistic guys, you will never get you money back at this stock, this isnshorts wonderland
0 · Reply
MrAlientrader
MrAlientrader Feb. 17 at 9:16 PM
$ADTX i will short the spike immediately after RS
0 · Reply
___ReversalsTrackerz
___ReversalsTrackerz Feb. 17 at 6:22 PM
$RETO $REED $DCX $ADTX ••
0 · Reply
MYBE
MYBE Feb. 17 at 4:50 PM
$ADTX $ADTX Does anyone know the total number of shares of the company now (free-floating shares with owned and non-traded shares) and will new shares be injected before the upcoming split? 🤔
1 · Reply
MYBE
MYBE Feb. 17 at 4:46 PM
$ADTX $ADTX The next split ratio for this fraudulent management has been set at 1:50 and no date has been set for the new split to take place. 😡😡😡😡
0 · Reply
NoEmotionzTrade
NoEmotionzTrade Feb. 17 at 10:38 AM
Ticker - OLB a quick double is possible and it is trading at depressed levels while small-cap momentum rotates. Historically, oversold bases like this can produce sharp percentage moves once buyers return. $HPCO $ADTX $ENSC $TBLT
0 · Reply
MalekJ
MalekJ Feb. 16 at 1:04 PM
$ADTX
0 · Reply
fr3ddyCab
fr3ddyCab Feb. 15 at 11:25 AM
$ADTX Brian Michael Brady, a director of ADiTx Inc., has reported a disposal of common shares of the company.
0 · Reply
exile0002
exile0002 Feb. 13 at 11:46 PM
$ADTX and the next RS ahead ..... do you recognized for what this stock is used since years ??? If you want to loose your money, invest your money here ... !👎👎👎
0 · Reply
MalekJ
MalekJ Feb. 13 at 10:36 PM
$ADTX it didn’t pass in Jan 30 2026 meetin.
1 · Reply
Kinkygaijin
Kinkygaijin Feb. 13 at 8:56 PM
$ADTX they have done RS every year for last 6 years why it won’t pass this time 😂
0 · Reply
CheesyRegard
CheesyRegard Feb. 13 at 5:19 PM
$ADTX I expect the next RS to be announced Friday Feb 27 after-hours, effective March 3 or 4. Y'all even voted Yes on giving them a bonus 350k shares after they burned all your money... you guys make it too easy for these scammers.
0 · Reply
MalekJ
MalekJ Feb. 13 at 2:44 PM
$ADTX Vote needs to pass even with the revers split proposal for the share price to start increasing for the short-term IMO. Let’s see, trade your plan.
0 · Reply